Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Publication Type:

Journal Article


JAMA : the journal of the American Medical Association, Volume 301, Issue 22, p.2349-61 (2009)


2009, Antineoplastic Agents, Clinical Research Division, Clinical Trials as Topic, Humans, Leukemia, Myeloid, Acute, Public Health Sciences Division, Remission Induction, Risk Assessment, Stem Cell Transplantation, Survival Analysis, Transplantation, Homologous


The optimal treatment of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends myeloablative allogeneic stem cell transplantation (SCT) for poor-risk but not for good-risk AML. Allogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent benefit for intermediate-risk AML.